Federally-Listed PSOs

Below is a list of PSOs that are currently listed by AHRQ. A health care provider can only obtain the confidentiality and privilege protections of the Patient Safety Act by working with a Federally-listed PSO.

Use the categories on the left to filter the list of PSOs or search a PSO name.

Note: AHRQ updates the PSO information contained within the directories weekly, as needed; changes are made when there are newly listed PSOs and/or when existing information requires revision. Changes that would otherwise be effective on a weekend day or holiday will be effective on the next business day. Information contained in the directories is based on attestations that the PSOs provide. To update PSO contact information, please use the Change of Listing Information form; to update profile information, please go to the PSO PPC Web site.

There are 87 total PSOs listed by AHRQ.

PLEASE NOTE: To search for a PSO by State, use the 2 letter state abbreviation. Example: Kansas = KS

Academic Medical Center (AMC) PSO - P0103
Component of Parent Org(s):
  • Risk Management Foundation of the Harvard Medical Institutions, Inc.
Effective Date and Time of Initial Listing: December 22, 2010 12:01 AM ET
PSO Mailing Address: c/o CRICO/RMF, 1325 Boylston Street, Boston, MA 02215
PSO Phone Number: 617-450-5586
Point of Contact: Joanne Locke
Point of Contact Phone: 617-450-6873
Point of Contact Email: jlocke2@rmf.harvard.edu (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 12/22/2018 through 12/21/2020
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
UHS Acute Care PSO - P0110
Component of Parent Org(s):
  • UHS of Delaware, Inc.
Effective Date and Time of Initial Listing: April 22, 2014 12:01 AM ET
PSO Mailing Address: 367 South Gulph Road, King of Prussia, PA 19406
PSO Phone Number: (610) 382-3385
Point of Contact: Heidi Speirs
Point of Contact Phone: (610) 382-1057
Point of Contact Email: heidi.speirs@uhsinc.com (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 04/22/2018 through 04/21/2020
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: Yes